NELL-1, an Osteoinductive Factor, Is a Direct Transcriptional Target of Osterix
- University of California, Los Angeles, CA (United States); Peking University, Beijing (China); DOE/OSTI
- University of California, Los Angeles, CA (United States)
- Oak Ridge National Laboratory (ORNL), Oak Ridge, TN (United States)
NELL-1 is a novel secreted protein associated with premature fusion of cranial sutures in craniosynostosis that has been found to promote osteoblast cell differentiation and mineralization. Our previous study showed that Runx2, the key transcription factor in osteoblast differentiation, transactivates the NELL-1 promoter. In this study, we evaluated the regulatory involvement and mechanisms of Osterix, an essential transcription factor of osteoblasts, in NELL-1 gene expression and function. Promoter analysis showed a cluster of potential Sp1 sites (Sp1/Osterix binding sites) within approximately 70 bp (from –71 to –142) of the 5' flanking region of the human NELL-1 transcriptional start site. Luciferase activity in our NELL-1 promoter reporter systems was significantly decreased in Saos-2 cells when Osterix was overexpressed. Mutagenesis study demonstrated that this suppression is mediated by the Sp1 sites. The binding specificity of Osterix to these Sp1 sites was confirmed in Saos-2 cells and primary human osteoblasts by EMSA in vitro and ChIP assay in vivo. ChIP assay also showed that Osterix downregulated NELL-1 by affecting binding of RNA polymerase II to the NELL-1 promoter, but not by competing with Runx2 binding to the OSE2 sites. Moreover, NELL-1 mRNA levels were significantly decreased when Osterix was overexpressed in Saos-2, U2OS, Hela and Glioma cells. Correspondingly, knockdown of Osterix increased NELL-1 transcription and osteoblastic differentiation in both Saos-2 cells and primary human osteoblasts. These results suggest that Osterix is a direct transcriptional regulator with repressive effect on NELL-1 gene expression, contributing to a delicate balance of regulatory effects on NELL-1 transcription with Runx2, and may play a crucial role in osteoblast differentiation and mineralization. These findings also extend our understanding of the molecular mechanism of Runx2, Osterix, and NELL-1 and demonstrate their crosstalk during osteogenesis.
- Research Organization:
- Oak Ridge National Laboratory (ORNL), Oak Ridge, TN (United States)
- Sponsoring Organization:
- National Institutes of Health (NIH); Thomas R. Bales Endowed Chair; UC Discovery; USDOE Office of Science (SC), Biological and Environmental Research (BER)
- Grant/Contract Number:
- AC05-00OR22725
- OSTI ID:
- 1627474
- Journal Information:
- PLoS ONE, Journal Name: PLoS ONE Journal Issue: 9 Vol. 6; ISSN 1932-6203
- Publisher:
- Public Library of ScienceCopyright Statement
- Country of Publication:
- United States
- Language:
- English
Genome-Wide Patterns of Genetic Variation in Two Domestic Chickens
|
journal | June 2013 |
Bone Microstructure and Regional Distribution of Osteoblast and Osteoclast Activity in the Osteonecrotic Femoral Head
|
journal | May 2014 |
Comparative Gene-Expression Analysis of the Dental Follicle and Periodontal Ligament in Humans
|
journal | December 2013 |
Similar Records
NELL-1 in the treatment of osteoporotic bone loss
Osterix enhances proliferation and osteogenic potential of bone marrow stromal cells
Collagen-derived dipeptide prolyl-hydroxyproline promotes differentiation of MC3T3-E1 osteoblastic cells
Journal Article
·
Tue Jun 16 20:00:00 EDT 2015
· Nature Communications
·
OSTI ID:1333652
Osterix enhances proliferation and osteogenic potential of bone marrow stromal cells
Journal Article
·
Thu Mar 23 23:00:00 EST 2006
· Biochemical and Biophysical Research Communications
·
OSTI ID:20798859
Collagen-derived dipeptide prolyl-hydroxyproline promotes differentiation of MC3T3-E1 osteoblastic cells
Journal Article
·
Fri Oct 24 00:00:00 EDT 2014
· Biochemical and Biophysical Research Communications
·
OSTI ID:22416799